Key terms
About NYXH
Nyxoah SA is a medical technology company, which engages in the development and commercialization of solutions to treat Obstructive Sleep Apnea (OSA). Its solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe OSA. The company was founded by Robert Taub and Adi Mashiach on July 15, 2009, and is headquartered in Mont-Saint-Guibert, Belgium.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest NYXH news
Apr 16
7:00am ET
Analysts Offer Insights on Healthcare Companies: Envista Holdings (NVST), Nyxoah (NYXH) and Zoetis (ZTS)
Apr 15
9:02pm ET
Nyxoah SA Welcomes New Chief Medical Officer
Apr 11
4:34pm ET
Nyxoah appoints Maurits Boon as chief medical officer
Mar 25
9:45am ET
Buy Rating Affirmed for Nyxoah’s Genio System Amid Strategic Partnerships and Market Capture Potential
Mar 25
5:13am ET
Nyxoah partners with AAO-HNSF
Mar 20
8:00am ET
Analysts Offer Insights on Healthcare Companies: Nyxoah (NYXH), Tyra Bioscience (TYRA) and Crinetics Pharmaceuticals (CRNX)
Mar 20
7:16am ET
Piper Sandler Keeps Their Buy Rating on Nyxoah (NYXH)
Mar 20
6:36am ET
Nyxoah price target raised to $27 from $20 at Stifel
Mar 20
6:15am ET
Buy Rating Affirmed for Nyxoah Amid Promising DREAM Study Results and Market Growth Projections
Mar 20
6:07am ET
Nyxoah price target raised to $22 from $18 at H.C. Wainwright
Mar 19
9:27pm ET
Nyxoah’s Genio System Shows Promise in OSA Study
Mar 19
4:20pm ET
Nyxoah announces DREAM study meets primary endpoints
Mar 14
7:40am ET
Analysts’ Top Healthcare Picks: Belite Bio, Inc. ADR (BLTE), Catalyst Pharma (CPRX)
Mar 06
8:12am ET
Nyxoah price target raised to $17 from $12 at Oppenheimer
Mar 06
8:00am ET
Analysts Offer Insights on Healthcare Companies: Nyxoah (NYXH), Ionis Pharmaceuticals (IONS) and Fusion Pharmaceuticals (FUSN)
Mar 06
7:17am ET
Nyxoah price target raised to $20 from $15 at Piper Sandler
Mar 06
6:56am ET
Nyxoah price target raised to $13.03 from $5.49 at Baird
Mar 06
6:28am ET
Buy Rating Affirmed for Nyxoah Amid Record Genio Sales and Strong Growth Prospects
Mar 05
9:09am ET
Nyxoah price target raised to $20 from $10 at Stifel
Feb 28
6:07am ET
Nyxoah price target raised to $18 from $15 at H.C. Wainwright
Feb 15
6:30am ET
Analysts Offer Insights on Healthcare Companies: Anavex Life Sciences (AVXL), PolyPid (PYPD) and Nyxoah (NYXH)
Feb 09
7:25am ET
Nyxoah price target raised to $14 from $10 at Cantor Fitzgerald
Feb 07
10:23am ET
Cantor Fitzgerald medtech analyst to hold an analyst/indusry conference call
Feb 01
8:49am ET
Nyxoah price target raised to $15 from $10 at Piper Sandler
Feb 01
8:09am ET
Nyxoah (NYXH) Receives a Buy from Piper Sandler
Jan 29
4:21pm ET
Nyxoah Stock (NASDAQ:NYXH): Don’t You Dare Sleep on This Little Runner
No recent press releases are available for NYXH
NYXH Financials
Key terms
Ad Feedback
NYXH Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
NYXH Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
